KSI-101 is poised to fulfill the core unmet need in MESI based on its potential to be a disease modifying, high-strength, locally administered and safe biologic Safety Efficacy Illustrative IVT anti-VEGF monotherapy Systemic immuno- suppressants High Less complications 1. Dual anti-IL-6 and anti-VEGF inhibition 2. Potential for disease modifying effect based on its synergistic inhibition of IL-6 and VEGF, as demonstrated in preclinical models and clinical cases 3. High strength formulation (100 mg/mL) and high potency provide the fire-power needed to treat “angry” inflammation and macular edema 4. Local (intravitreal) administration 5. Safety profile in line with intravitreally administered biologics (i.e., Eylea, Lucentis) KSI-101 is designed to address the core unmet need Core unmet need open Steroids 49 1. Targets both IL-6 & VEGF disease drivers 2. Potentially disease modifying 3. High strength 4. Potent 5. Minimally invasive 6. Better safety A unified treatment irrespective of presumed etiology